The UK National External Quality Assessment Service (UK NEQAS) distributes clinically relevant and educational specimens for external quality assessment (EQA). The aim of this report was to assess the suitability of using a freeze-dried specimen format for the EQA of conventional and rapid methods and to review the methods used by participants to screen for meticillin-resistant Staphylococcus aureus (MRSA). Of the 714 laboratories that returned a result, 678 reported the presence of MRSA, and results showed a mean of 73 c.f.u. per 25 ml and a median of 50 c.f.u. per 25 ml confirming that the specimen was homogeneous. Four different approaches to MRSA screening were used routinely, including: (i) liquid culture; (ii) direct plating onto conventional media; (iii) direct plating onto chromogenic media; and (iv) rapid methods. A wide variety of methods were used within each of these four categories to screen for MRSA, and many laboratories reported using more than one method. Attempts should be made to determine the most appropriate approach to MRSA screening and to standardize the protocols across the UK.
INTRODUCTION
Colonization provides a reservoir from which bacteria, such as Staphylococcus aureus, can be introduced when host defences are breached and increases the risk for subsequent infection. Individuals with S. aureus infections are generally infected with their colonizing strain. Colonization also allows S. aureus to be transmitted among individuals in both healthcare and community settings and is a significant contributor to prolonged hospital stay, poor clinical outcomes and increased healthcare costs amongst surgical patients (Gordon & Lowy, 2008) .
The transmission of meticillin-resistant S. aureus (MRSA) and the risk of MRSA infection (including MRSA bacteraemia) in hospitals and care facilities can be addressed if MRSA carriers are identified and treated. This requires screening of patient populations for MRSA carriage either before or on admission to identify carriers and implement a decolonization regimen (Department of Health, 2006) . Evidence from the literature shows that active screening for MRSA and subsequent control measures lead to a reduction in the incidence of MRSA infections. Screening is the only strategy with proven efficacy in high endemic settings (Kluytmans, 2007) .
The UK has one of the highest rates of infection and colonization of MRSA within Europe and the need for improved intervention has been highlighted by experts in infection control (Hardy et al., 2007) There has been little consistent or definitive advice to the NHS on which patients to screen, how to screen them and when. There is also a high degree of variability in practice in NHS trusts and there is no single recommendation with a strong and incontrovertible evidence base that can be recommended uniformly for all NHS trusts. Currently, the choice is a matter for local assessment (Department of Health, 2006) .
The UK National External Quality Assessment Service (UK NEQAS) distributes clinically relevant and educational specimens for external quality assessment (EQA). The aim of this report was to assess the suitability of using a freeze-dried specimen format for the EQA of conventional and rapid methods and to review the methods used by participants to screen for MRSA.
METHODS
The UK NEQAS for Microbiology General Bacteriology EQA scheme has 742 participating laboratories from 16 EU and 19 non-EU countries. In January 2009, the General Bacteriology scheme, distribution 2395, included a specimen containing MRSA (10 3 c.f.u. ml 21 ) suitable for detection by direct culture on an MRSA-selective agar, broth enrichment followed by subculture and rapid (molecular and immunological) techniques. The specimen was distributed with a supplementary form asking participants for information on the methods and media that they used for MRSA screening as well as their results from the conventional and rapid methods used.
RESULTS AND DISCUSSION
Of the 742 laboratories participating in the scheme, 714 laboratories returned a result. In total, 678 laboratories reported the presence of MRSA, 26 reported a negative result or MRSA not detected, and 10 (all non-UK laboratories) reported S. aureus detected. Of the 26 laboratories that failed to detect MRSA, 10 completed the supplementary form and four stated that they used Oxoid Selective Mannitol broth containing ciprofloxacin (Kelly et al., 2004) .
Overall, 12 of the 714 laboratories stated that they used Oxoid Selective Mannitol broth. Ten of the 12 laboratories that used Oxoid Selective Mannitol broth failed to isolate MRSA with this medium as the strain was ciprofloxacinsensitive. Five of the laboratories that failed to detect MRSA using Oxoid Selective Mannitol broth used alternative methods to isolate the pathogen, for example direct plating onto chromogenic agar. It is unlikely that this level of investigation would be applied to all routine specimens and ciprofloxacin-sensitive MRSA would not be detected using Oxoid Selective Mannitol broth. In the UK, most hospital isolates are ciprofloxacin-resistant but this is not necessarily the case for community-acquired isolates and types prevalent in other countries (Brown et al., 2005) .
The results of the questionnaire showed that a wide range of screening methods were used including liquid culture (enrichment and selective) media (29 %; 124/424) and culture, conventional solid agar (32 %; 137/424), chromogenic media (86 %; 364/424) and rapid methods (23 %; 98/ 424). Nutrient broth was the most commonly used enrichment broth (34/124) but approximately 45 other commercial or in-house broths were reported (Table 1) .
Mannitol Salt agar, Mueller-Hinton agar and Oxacillin
Resistant Screening agar are the most common conventional solid agars used although again a wide variety were reported (Table 1) . The most common approach was to use chromogenic media. Analysis of a previous UK NEQAS questionnaire sent to participants in 2007 showed MRSA-ID (now known as bioMérieux chromID MRSA) and Chromogenic MRSA agar (Oxoid) were the most popular chromogenic agars and the results of this survey show that this is still the case (Table 1 ) (Tande et al., 2008; Carson et al., 2009; van Hal et al., 2009 ).
Participants were requested to reconstitute the freeze-dried specimen in 1 ml broth and apply 'a drop from a pasteur pipette or dipped swab as the inoculum'. Pre-distribution tests performed in-house showed colony counts of between 38 and 50 c.f.u. per 'drop' (a 'drop' is defined here as 25 ml). Participants' results showed a mean of 73 c.f.u. per 25 ml and a median of 50 c.f.u. per 25 ml confirming that the specimen was homogeneous.
Ninety-seven laboratories (21 of which were in the UK) used rapid methods, with Cepheid Xpert MRSA (22) and BD GeneOhm (20) being the most popular commercial methods, although 33 participants reported using an inhouse assay (Table 1 ) (van Hal et al., 2009; Wolk et al., 2009; Svent-Kucina et al., 2009) . The UK NEQAS questionnaire in 2007 showed that 32 laboratories (three of which were UK laboratories) were using molecular methods, illustrating that the number of laboratories implementing molecular methods has increased. Seventythree (17 of which were UK laboratories) of the 97 laboratories who reported that they routinely use a molecular assay reported a result. Sixty-eight of these reported the correct result. The five incorrect results were not associated with the use of any particular assay (four were commercial assays, whilst one was an in-house assay). Therefore, 93 % of laboratories using rapid methods reported the correct result, which compares favourably with the percentage of laboratories that reported a correct result using conventional methods (95 %).
The data from the supplementary questionnaire demonstrated that four different approaches to MRSA screening were used routinely, including: (i) liquid culture; (ii) direct plating onto conventional media; (iii) direct plating onto chromogenic media; and (iv) rapid methods. Liquid culture was used for detection, selection and enrichment in combination with either conventional media or chromogenic media. A wide variety of methods were used within each of these four categories to screen for MRSA, and many laboratories reported using more than one method.
The UK Department of Health has recommended that hospital trusts should review their policies for MRSA screening to determine the most appropriate initial approach for their patient population. EQA can assist laboratories in reviewing their screening procedures, deciding which assay to adopt and determine whether a robust screening programme is in place. In addition, many laboratories are implementing molecular assays and EQA can contribute to the development and validation of these novel molecular protocols.
